Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Ovarian Cancer
Do you offer PARP inhibitor maintenance therapy to stage IC high grade serous ovarian cancer patients?
Related Questions
What are your top takeaways in Gyn Cancers from ESMO 2024?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?
How does your management and counseling of a patient with ovarian cancer change when they have significant persistent disease after neoadjuvant chemotherapy?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?
How would you manage concurrent immunotherapy-related colitis and C. difficile infection?
What are your top takeaways in Gyn Cancers from ASCO 2025?
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
